Quintrio
Home

PHARMACEUTICAL PREPARATIONS

SELLAS Life Sciences Group, Inc. Common Stock

SLS

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Last trade $19.45
Day change +$11.98 (+160.31%)
Day range $7.62 – $33.36
Volume 104,836,896
Market cap $1.52B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.52B
Price / earnings
—
Price / book
11.55×
Price / sales
—
EV / sales
—
EV / EBITDA
-35.19×

Profitability

Earnings per share
-$0.18
Return on assets
-25.35%
Return on equity
-27.13%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
14.92×
Quick ratio
14.92×
Cash ratio
14.51×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.3M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SLS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.28M$4.36M$4.12M$3.53M$2.87M$3M$2.86M$2.48M
Research and development$7.03M$6.27M$5.13M$4.73M$4.22M$3.87M$3.21M$4.44M
Total operating expenses$11.31M$10.63M$9.25M$8.26M$7.08M$6.87M$6.06M$6.92M
Operating income-$11.31M-$10.63M-$9.25M-$8.26M-$7.08M-$6.87M-$6.06M-$6.92M
Interest expense$1.22M$0$0$0$292K$0$0$0
Income before taxes-$10.09M-$9.61M-$8.41M-$7.66M-$6.79M-$6.6M-$5.81M-$6.74M
Income taxes$0$0$0$0$0$0$0$0
Net income-$10.09M-$9.61M-$8.41M-$7.66M-$6.79M-$6.6M-$5.81M-$6.74M
Net income attributable to common shareholders-$10.09M-$9.61M-$8.41M-$7.66M-$6.79M-$6.6M-$5.81M-$6.74M
EBITDA-$11.31M-$10.63M-$9.25M-$8.26M-$7.08M-$6.87M-$6.06M-$6.92M
Basic earnings per share-$0.05-$0.05-$0.05-$0.05-$0.06-$0.07-$0.07-$0.09
Diluted earnings per share-$0.05-$0.05-$0.05-$0.05-$0.06-$0.07-$0.07-$0.09

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia

SELLAS Life Sciences announced positive topline results from its Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid leukemia. GPS demonstrated a statistically significant 41% reduction in risk of death with median overall survival of 24.0 months versus 14.7 months for best available treatment (hazard ratio 0.59, p=0.035). The company plans to meet with the FDA and submit a Biologics License Application in the first half of 2027.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

Pomerantz LLP is investigating potential securities fraud claims against SELLAS Life Sciences Group, Inc. following reports that the company failed to timely release phase 3 clinical trial results for Galinpepimut-S after reaching a pre-specified trigger event (80th patient death). The stock declined 13.15% to $13.21 per share on August 28, 2026, following the news.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Mar 24, 2011$240.30Apr 5, 2011unknown
Dec 9, 2010$421.30Dec 20, 2010unknown
Sep 9, 2010$150.00Sep 22, 2010unknown
Jun 10, 2010$85.00Jun 21, 2010unknown
Mar 18, 2010$85.00Mar 29, 2010unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 8, 20191-for-50reverse split
Nov 14, 20161-for-20reverse split